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In 2002, we investigated a cluster of patients with Al-
caligenes xylosoxidans bloodstream infections by conduct-
ing a matched case–control study and a prospective study. 
Pulsed-ﬁ  eld gel electrophoresis (PFGE) was performed on 
blood culture isolates, and 1 explanted central venous cath-
eter (CVC) was tested for bioﬁ  lm. We identiﬁ  ed 12 cases of 
A. xylosoxidans bloodstream infection. Case-patients were 
more likely than controls to have had a CVC (7/7 [100%] 
vs 4/47 [8.7%], respectively; p<0.0001). Ten case isolates 
were indistinguishable by PFGE analysis, and A. xylosoxi-
dans bioﬁ  lm from the CVC matched the outbreak strain. We 
observed multiple breaches in infection control, which may 
have caused contamination of multidose vials used to ﬂ  ush 
the CVCs. Our study links A. xylosoxidans with CVC bioﬁ  lm 
and highlights areas for regulation and oversight in outpa-
tient settings.
A
lcaligenes xylosoxidans, also known as Achromobacter
xylosoxidans, is a gram-negative, water-borne organ-
ism  that  causes  healthcare-associated  infections  (1–7)
and bacteremia in immunocompromised patients with in-
dwelling catheters (6–11); it can also contaminate liquids 
(2,5,12–14). A. xylosoxidans is found in soil and water and 
grows in saline (15,16). On January 16, 2002, the Acute 
Communicable Disease Control (ACDC) program of the 
Los Angeles County Department of Public Health was no-
ti? ed by a local hospital epidemiologist about a cluster of 
patients with A. xylosoxidans bloodstream infections (17).
The patients had been admitted to Hospital A over a period 
of 2 months.
To con? rm the presence of an outbreak, ACDC con-
ducted a telephone survey, which asked the microbiology 
laboratories of Hospital A and 4 surrounding hospitals for 
a list of all patients who had had positive blood cultures 
for A. xylosoxidans in the past 3 months. One laboratory 
identi? ed 3 such patients, and Hospital A laboratory iden-
ti? ed 7; all 9 patients (1 case-patient had positive blood 
Alcaligenes xylosoxidans
Bloodstream Infections in 
Outpatient Oncology Ofﬁ  ce
Moon J. Kim,* Elizabeth Bancroft,* Eleanor Lehnkering,* Rodney M. Donlan,† and Laurene Mascola*
RESEARCH
8 0 0 2   y l u J   , 7   . o N   , 4 1   . l o V   •   d i e / v o g . c d c . w w w   •   s e s a e s i D   s u o i t c e f n I   g n i g r e m E   6 4 0 1
*Los Angeles County Department of Public Health, Los Angeles, 
California, USA; and †Centers for Disease Control and Prevention, 
Atlanta, Georgia, USA
DOI: 10.3201/eid1407.070894
CME ACTIVITY
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity 
to earn CME credit. Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for 
physicians. Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only 
claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certi? -
cate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education 
content; (3) take the post-test and/or complete the evaluation at http://www.medscape.com/cme/eid; (4) view/print certi? cate.
Learning Objectives
Upon completion of this activity, participants will be able to:
Identify properties of  •  Alcaligenes xylosoxidans.
Describe the clinical presentation of  •  A. xylosoxidans infection in the current study.
Specify risk factors for infection with  •  A. xylosoxidans.
Identify the primary source of infection with  •  A. xylosoxidans in the current study.
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CME Questions
Activity Evaluation
1. Which of the following statements about Alcaligenes
xylosoxidans is most accurate?
A. A. xylosoxidans is gram-positive
B. A. xylosoxidans is hydrophobic
C. A. xylosoxidans is associated with healthcare-associated 
infections
D. A. xylosoxidans is found only in soil
2. Which of the following statements about the clinical 
presentation of A. xylosoxidans infection in the current study 
is most accurate?
A.   No patients with A. xylosoxidans infection were 
immunocompromised
B.   Patients with A. xylosoxidans were homogeneous with regard 
to age and clinical diagnosis
C.   Patients with A. xylosoxidans infection had symptoms that 
were attributed to side effects of chemotherapy
D.   Only 10% of patients with A. xylosoxidans infection were 
successfully treated with antibiotics
3. Which of the following factors was most different in 
comparing case-patients and control groups in the current 
study?
A.   Case-patients with A. xylosoxidans infection had a lower 
mean white blood cell count compared with controls
B.   Case-patients with A. xylosoxidans infection were more likely 
to have a central venous catheter compared with controls
C.   Case-patients with A. xylosoxidans infection had a greater 
number of intravenous medications administered compared 
with controls
D.   Case-patients with A. xylosoxidans infection had more 
underlying diseases compared with controls
4. Which of the following sources was most likely the primary 
reservoir of A. xylosoxidans in the current study?
A.   Tap water
B.   Mixing hood
C.   Hospital personnel
D.   Multidose vials of heparin and saline ﬂ  ushes
1. The activity supported the learning objectives. 
Strongly Disagree Strongly Agree 
1 5 4 3 2
2. The material was organized clearly for learning to occur.
Strongly Disagree Strongly Agree
5 4 3 2 1
3. The content learned from this activity will impact my practice.
Strongly Disagree Strongly Agree
5 4 3 2 1
4. The activity was presented objectively and free of commercial bias.
Strongly Disagree Strongly Agree
5 4 3 2 1